Psychological Medicine, Page 1 of 13. © Cambridge University Press 2017
doi:10.1017/S0033291717002914

ORIGINAL ARTICLE

Acute LSD effects on response inhibition neural networks

A. Schmidt[1]*, F. Müller[1], C. Lenz[1], P. C. Dolder[2], Y. Schmid[2], D. Zanchi[1], U. E. Lang[1], M. E. Liechti[2] and S. Borgwardt[1]

[1] *Department of Psychiatry (UPK), University of Basel, Basel, Switzerland*
[2] *Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University of Basel, University Hospital Basel, Basel, Switzerland*

Background. Recent evidence shows that the serotonin 2A receptor (5-hydroxytryptamine2A receptor, 5-HT_{2A}R) is critically involved in the formation of visual hallucinations and cognitive impairments in lysergic acid diethylamide (LSD)-induced states and neuropsychiatric diseases. However, the interaction between 5-HT_{2A}R activation, cognitive impairments and visual hallucinations is still poorly understood. This study explored the effect of 5-HT_{2A}R activation on response inhibition neural networks in healthy subjects by using LSD and further tested whether brain activation during response inhibition under LSD exposure was related to LSD-induced visual hallucinations.

Methods. In a double-blind, randomized, placebo-controlled, cross-over study, LSD (100 μg) and placebo were administered to 18 healthy subjects. Response inhibition was assessed using a functional magnetic resonance imaging Go/No-Go task. LSD-induced visual hallucinations were measured using the 5 Dimensions of Altered States of Consciousness (5D-ASC) questionnaire.

Results. Relative to placebo, LSD administration impaired inhibitory performance and reduced brain activation in the right middle temporal gyrus, superior/middle/inferior frontal gyrus and anterior cingulate cortex and in the left superior frontal and postcentral gyrus and cerebellum. Parahippocampal activation during response inhibition was differently related to inhibitory performance after placebo and LSD administration. Finally, activation in the left superior frontal gyrus under LSD exposure was negatively related to LSD-induced cognitive impairments and visual imagery.

Conclusion. Our findings show that 5-HT_{2A}R activation by LSD leads to a hippocampal–prefrontal cortex-mediated breakdown of inhibitory processing, which might subsequently promote the formation of LSD-induced visual imageries. These findings help to better understand the neuropsychopharmacological mechanisms of visual hallucinations in LSD-induced states and neuropsychiatric disorders.

Received 27 March 2017; Revised 5 September 2017; Accepted 6 September 2017

Key words: Cognitive control, fMRI, LSD, visual hallucinations.

Introduction

Classic hallucinogens like lysergic acid diethylamide (LSD) and psilocybin constitute two candidate models of psychosis that have widely been used to unravel neurobiological mechanisms of psychotic symptoms most relevant to the pathophysiology of schizophrenia (Vollenweider & Geyer, 2001; Geyer & Vollenweider, 2008; González-Maeso & Sealfon, 2009; Carhart-Harris *et al.* 2013; Halberstadt & Geyer, 2013; De Gregorio *et al.* 2016). Hallucinogens such as LSD and psilocybin induce agitation, anxiety, visual hallucinations and illusion, which are reminiscent of those observed in the first episode of psychosis (Steeds *et al.* 2015). Apart their potential to mimic some psychotic symptoms, LSD and psilocybin are particularly useful to temporally and profoundly alter an individual's visual experiences (Kometer & Vollenweider, 2016). Activation of 5-hydroxytryptamine2A receptors (5-HT_{2A}Rs) predominantly mediates the visual hallucinations that are induced by psilocybin (Vollenweider *et al.* 1998; Kometer *et al.* 2013) and LSD (Preller *et al.* 2017) and administration of the 5-HT_{2A}R inverse agonist pimavanserin is effective for treatment of visual hallucinations in patients with Parkinson's disease psychosis (Meltzer *et al.* 2010). Therefore, 5-HT_{2A}R activation by LSD helps to study the neuropsychopharmacological mechanisms of visual hallucinations with implications for the pathophysiology of visual hallucinations in psychiatric disorders (Kometer & Vollenweider, 2016).

* Address for correspondence: A. Schmidt, Ph.D., Department of Psychiatry (UPK), University of Basel, Wilhelm Klein Strasse 27, Basel 4012, Switzerland.
(Email: andre.schmidt@unibas.ch)

Recent studies demonstrated that acute LSD administration to healthy subjects not only produces elementary and complex visual pseudo-hallucinations and perceptual illusions (Schmid *et al.* 2015; Carhart-Harris *et al.* 2016*b*; Preller *et al.* 2017), but also impaired inhibitory processes (prepulse inhibition) (Schmid *et al.* 2015) and induced cognitive disorganization (Carhart-Harris *et al.* 2016*a*). These findings are in line with studies from the 1960s showing that LSD impairs inhibitory performance on the Stroop Test (Wapner & Krus, 1960; Krus *et al.* 1963). Of note, impairments in prepulse inhibition after psilocybin administration and cognitive impairments after LSD administration were attenuated by administration of the 5-HT_{2A}R antagonist ketanserin (Quednow *et al.* 2011; Preller *et al.* 2017), indicating that 5-HT_{2A}R activation is not only responsible for visual hallucinations but also cognitive impairments after LSD or psilocybin intake. 5-HT_{2A}Rs are indeed critically involved in different cognitive functions (Štrac *et al.* 2016) and abnormal 5-HT_{2A}R activity is associated with cognitive impairments in a number of psychiatric disorders (Zhang & Stackman, 2015). Furthermore, 5-HT_{2A}R antagonists induce at least modest improvement in cognition in schizophrenia and might also help to enhance cognition in other disorders such as dementia (Roth *et al.* 2004).

Cognitive impairments and visual hallucinations do often co-exist. Executive functions are involved in reality monitoring and contribute significantly to disentangling visual perception (Barnes & Boubert, 2008), from determining external and internal stimuli, to the internal production of a visual image (Roth *et al.* 2009). A previous study could show that Parkinson patients with visual hallucination have substantially greater impairments of inhibitory ability than those without visual hallucination (Barnes & Boubert, 2008). Another study supported this result by showing that within patients with Parkinson's and Alzheimer's disease, those with visual hallucinations scored significantly lower than patients without visual hallucinations, particularly on tests evaluating prefrontal-executive functions such as inhibition (Grossi *et al.* 2011). Theoretical reflections propose that 5-HT_{2A}R activation may cause a cognitive disability to integrate new perception that subsequently triggers the formation of aberrant feelings and visual perception (Vollenweider & Geyer, 2001; Geyer & Vollenweider, 2008).

In this study, we first tested the relationship between subjective LSD-induced cognitive impairments and visual imageries in healthy subjects. We then explored the acute effect of LSD on response inhibition neural networks (Go/No-Go task) and whether this effect was related to subjective feelings of impaired cognitive control and visual imageries. Based on the evidence showing a relationship between prefrontal-mediated cognitive impairments and visual hallucinations in Parkinson patients and theories proposing that 5-HT_{2A}R stimulation by classical hallucinogens might promote visual hallucination through a cognitive failure to integrate external stimuli, we first expected a positive relationship between LSD effects on subjective feelings of cognitive control and visual imageries. Our second hypothesis was that LSD would reduce activation in prefrontal regions underlying response inhibition such as the middle, superior and inferior frontal gyrus, middle temporal gyrus, pre-supplementary motor area, anterior cingulate cortex and putamen (Simmonds *et al.* 2008; Swick *et al.* 2011) and that this effect would be positively related to LSD-induced formation of visual hallucinations.

Methods

The study was approved by the Ethics Committee for Northwest/Central Switzerland (EKNZ) and by the Federal Office of Public Health. The study was registered at ClinicalTrials.gov prior to study start (NCT02308969).

Participants

Twenty-four subjects were recruited from the University of Basel campus by online advertisement and word of mouth. Exclusion criteria were age <25 or >65 years, physical illness (as determined by medical history and general medical examination including ECG, blood chemistry and haematology), pregnancy (as determined by urine test), nursing, use of medication that could interfere with effects of the study medication, use of illicit drugs more than 10 times a life time (except cannabis) or any time within the previous 2 months, smoking of >10 cigarettes/day, history of substance dependence, personal or first-degree relative with an axis I major psychiatric disorder (as determined by a semi-structured interview for DSM-IV). Occasional recreational use of illicit drugs (stimulants, psychedelics, opioids, etc.) in the past (<10 times) was not an exclusion criterion if no adverse reactions occurred. Subjects were asked to abstain from any illicit drug use during the study and drug screens were performed during screening and randomly before test sessions. Positive screens for stimulants, opioids or hallucinogens resulted in exclusion from the study. Moderate controlled cannabis consumption was accepted. Previous substance use is reported in the online Supplementary Table S1.

Subjects provided written informed consent and received monetary compensation for their participation.

Three participants did not perform the Go/No-Go task due to too much movement in preceding functional magnetic resonance imaging (fMRI) tasks (T1 sequence, resting state fMRI, arterial spin labeling, emotional face processing; total length of MRI scanning: approximately 60 min). Three other participants had to be excluded due to too much movement during the Go/No-Go task (see fMRI data analysis for more details), resulting in a final sample of 18 subjects (nine men, nine women; mean age: 31 ± 9 years, range: 25–58).

Drug administration

Using a placebo-controlled, double-blind, cross-over design, each participant completed two study sessions, with a washout period of at least 7 days between the sessions. Placebo or 100 µg LSD were administered orally at 9:00 hours, 2.5 h before the MRI scan, taking into account the subjective and pharmacological peak effects of LSD (Schmid *et al.* 2015; Dolder *et al.* 2015*a*, *b*, 2016, 2017).

Subjective LSD effects on cognitive control and visual perception

We used the 5 Dimensions of Altered States of Consciousness (5D-ASC) scale (Studerus *et al.* 2010) to assess LSD effects on cognitive control ('impaired cognition and control') and visual perception ('elementary/complex imagery') 3 h after LSD intake (Liechti *et al.* 2016). Impaired cognition and control comprised the following subitems: 'I felt like a marionette', 'I had difficulty making even the smallest decision', 'I had difficulty in distinguishing important from unimportant things', 'I felt as though I were paralysed', 'I felt isolated from everything and everyone', 'I was not able to complete a thought, my thought repeatedly became disconnected', 'I had the feeling that I no longer had a will of my own'. The factor elementary imagery contained items such as 'I saw regular patterns in complete darkness or with closed eyes', 'I saw colours before me in total darkness or with closed eyes', 'I saw lights or flashes of light in total darkness or with closed eyes', while the factor complex imagery included questions like 'I saw scenes rolling by in total darkness or with my eyes closed', 'I could see pictures from my past or fantasy extremely clearly' and 'my imagination was extremely vivid'.

Analysis of LSD plasma concentration

The results on plasma levels have already been published (Dolder *et al.* 2017). Because we adapted these data to the subjects included in the Go/No-Go task, we report here the measuring approach as well as the result for completeness. Plasma concentrations 0, 1, 2 and 3 h after LSD administration were determined using sensitive and validated liquid-chromatography-tandem mass-spectrometry methods as reported in detail elsewhere (Dolder *et al.* 2015*a*). The lower limit of quantification was 0.05 ng/ml (Dolder *et al.* 2015*a*). Relationships between LSD plasma concentrations and LSD effects on 'impaired cognition and control' and 'elementary/complex imagery' 3 h after drug administration were tested with Pearson correlation analyses (Bonferroni corrected for multiple testing: $p < 0.017$).

The Go/No-Go task

Approximately 200 min after drug administration, all patients underwent an event-related Go/No-Go fMRI paradigm that was conducted with jittered intertrial intervals and incorporated infrequently presented oddball stimuli to optimize statistical efficiency. The task is a well-validated paradigm used in previous fMRI studies (Rubia *et al.* 2006; Borgwardt *et al.* 2008; Schmidt *et al.* 2013; Daly *et al.* 2014; Schmidt *et al.* 2017) requiring either the execution or the inhibition of a motor response, depending on the visual presentation of the stimuli. The basic Go task is a choice reaction time paradigm, in which arrows point either to the left or to the right side for 500 ms, with a mean intertrial interval of 1800 ms (jitter range: 1600–2000 ms). During Go trials, subjects were instructed to press a left or right response button according to the direction of the arrow. In 12% of the trials, arrows pointing upward appeared. During these so-called 'No-Go' trials, participants were required to inhibit their motor response. During another 12% of the trials, arrows pointing left or right at a 22.5° angle were presented, and subjects were told to respond to these in the same way as for Go stimuli (even though they pointed obliquely). These 'oddball' stimuli were used to control for novelty effects associated with the low frequency and different orientation of the No-Go relative to the Go trials (stimulus-driven attention allocation). In total, there were 24 No-Go, 160 Go and 24 oddball trials, with task duration of approximately 6 min. For a graphical overview of the task, see online Supplementary Fig. S1.

Analyses of inhibitory performance and subjective drug effects

Behavioural task performance was evaluated by the probability of inhibition, correct number of Go trials and reaction time to Go trials. Treatment differences in task performance and 5D-ASC items were examined using paired *t* tests.

fMRI data acquisition and analysis

Scanning was performed on a 3 T scanner (Siemens Magnetom Verio; Siemens Healthcare, Erlangen, Germany), using an echo planar imaging (EPI) sequence with 2.5 s repetition time, 28 ms echo time, a matrix size of 76 × 76 and 38 slices with 0.5-mm inter-slice gap, providing a resolution of 3 mm × 3 mm × 3 mm and a field of view of 228 cm × 228 cm. In total, 160 volumes were acquired.

EPIs were analysed using an event-related design with SPM12 (www.fil.ion.ucl.ac.uk/spm). During pre-processing, images were realigned to the first image in the series, spatially normalized to the Montreal Neurological Institute (MNI) template and smoothed with a Gaussian kernel of 8 mm full half-width maximum. All volumes were quality checked for severe head motion and image artefacts (e.g. nose wrapping, aliasing, blurring, etc.). Furthermore, all volumes with more than 3 mm deviation from the previous volume in any dimension were excluded and replaced with the average of the neighbouring volumes. Subjects with more than 10% corrupted volumes (i.e. 3 mm deviation in any dimension) were excluded from further analysis. Following this procedure, three subjects were excluded.

Voxel-wise maximum likelihood parameter estimates were calculated during the first-level analysis using the general linear model. Our design matrix included an autoregressive AR(1) model of serial correlations and a high-pass filter with a cutoff of 128 s. Onset times for Go, No-Go and oddball trials were convolved with a canonical haemodynamic response function and motion parameters acquired during the realignment procedure were added to the individual design matrix as multiple regressors. Subject-specific condition effects during response inhibition (No-Go *v.* oddball trials), controlled for the attentional oddball effect due to the low-frequency occurrence of No-Go trials, were computed using *t*-contrasts, producing a contrast image propagated to the second-level analysis. A one-sample *t* test was performed to examine whole brain activation during response inhibition across all treatments (effect of task). Treatment differences between placebo and LSD were examined using a paired *t* test design. According to recent recommendations on cluster-extent-based thresholding in fMRI analysis (Woo *et al.* 2014), significance was assessed at a cluster-level threshold of $p < 0.05$ family-wise error (FWE) corrected across the whole brain, using an uncorrected cluster-forming threshold of $p < 0.001$ with an extent threshold of 20 voxels.

Relationship between brain activation and task performance

To test if the relationship between brain activation during response inhibition and the degree of successful inhibition (probability of inhibition) differed between the placebo and LSD treatment, we used a SPM two-sample *t* test design with probability of inhibition as covariate.

Relationship between brain activation, plasma concentration, cognitive impairments and visual perception

To test if LSD-induced brain activation during response inhibition was related to subjective feelings of cognitive impairments and visual hallucinations, as well as plasma concentrations (mean of 2 and 3 h measurements), we used a SPM one-sample test designs with 'impaired control and cognition', 'elementary imagery', 'complex imagery' or 'plasma concentration' as covariates, respectively.

Results

Subjective LSD effects on cognitive control and visual perception

LSD produced significantly higher scores than placebo for cognitive impairments and visual hallucination as indexed by impaired control and cognition ($t_{17} = -8.007$, $p < 0.0001$), elementary ($t_{17} = -9.099$, $p < 0.001$) and complex imagery ($t_{17} = -7.052$, $p < 0.001$), respectively (Fig. 1*a*). There was a significant positive correlation between impaired control/cognition and elementary ($r = 0.620$, $p = 0.006$, corrected for multiple testing) (Fig. 1*b*) but not complex ($r = 0.235$, $p = 0.347$) imagery after LSD intake.

LSD plasma concentrations

LSD plasma concentrations rapidly increased to 1.29 ng/mL (S.D. 0.722) and 1.33 ng/mL (S.D. 0.59) 1 and 2 h after administration, while the concentration then decreased to 1.15 ng/mL (S.D. 0.52) 3 h after intake (online Supplementary Fig. S2). The LSD plasma concentration was positively related to subjectively experienced visual imagery 3 h after LSD administration ($r = 0.56$, $p = 0.016$, corrected for multiple testing) (online Supplementary Fig. S3), while there was also a strong trend for a positive relationship to LSD-induced cognitive impairments ($r = 0.461$, $p = 0.054$).

Behavioural task performance

Relative to placebo (mean = 0.79, S.D. = 0.025), acute LSD administration (mean = 0.77, S.D. = 0.044) significantly reduced the probability of inhibition ($t_{17} = 2.19$, $p = 0.043$) (Fig. 2*a*). LSD (mean = 129.33, S.D. = 24.83) reduced the number of responses to Go trials compared with placebo (mean = 151.00, S.D. = 12.84) ($t_{17} = 4.23$, $p = 0.001$) (Fig. 2*b*). Furthermore, LSD (mean =



Fig. 1. (*a*) Subjective LSD effect on cognitive control (impaired control and cognition) and elementary and complex imagery. Error bars reflect standard errors. ***Indicates significant LSD effects at $p < 0.001$. (*b*) Significant positive correlation between impaired control and cognition and elementary imagery after LSD intake ($r = 0.620$, $p = 0.006$).

432.64, S.D. = 12.89) also prolonged reaction times to Go trials relative to placebo (mean = 413.90, S.D. = 27.10) ($t_{17} = -3.42$, $p = 0.003$) (Fig. 2*c*). Notably, the probability of inhibition under LSD was negatively related to subjective LSD feelings of impaired cognition and control ($r = -0.523$, $p = 0.026$).

Brain activation during response inhibition

Effect of task

Combined treatment maps revealed significant activation in frontal, striato-thalamic and cerebellar brain regions during response inhibition (online Supplementary Table S2).

LSD effects on brain activation during response inhibition

Relative to placebo, LSD significantly decreased activation in the right middle temporal, angular and inferior frontal gyrus, left postcentral gyrus, right anterior cingulate cortex and left cerebellum (Fig. 3*a*, Table 1).

Relationship between brain activation and task performance

The relationship between right parahippocampal activation during response inhibition and the probability of inhibition significantly differed across the placebo and LSD treatment (Fig. 3*b*). While this relationship was positive under placebo exposure ($r = 0.88$, $p < 0.001$), there was no such relationship after LSD administration ($r = -0.06$, $p = 0.8$) (Fig. 3*c*).

Relationship between brain activation, plasma concentration, cognitive impairments and visual perception

We found a significant negative relationship between the severity of subjectively experienced cognitive impairments and activation in the right middle frontal gyrus and right and left superior frontal gyrus (Figs 4*a* and 4*c*, online Supplementary Table S3). Furthermore, there was also a significant negative relationship between the severity of subjectively experienced elementary imagery and activation in the right precentral



Fig. 2. Task performance expressed as (*a*) probability of inhibition, (*b*) number of correct responses to Go trials and (*c*) reaction times to Go trials after placebo and LSD administration. Error bars reflect standard errors. *$p < 0.05$, **$p < 0.01$ and ***$p < 0.001$, significant differences in task performance between LSD and placebo.

gyrus and left superior frontal gyrus (Figs 4*b* and 4*d*, online Supplementary Table S4). We found no significant relationship between LSD plasma concentration and brain activation during response inhibition.

Discussion

Our study provided the following main findings: First, there was a positive relationship between LSD effects on subjective feelings of impaired cognitive control and visual imageries. Second, acute LSD administration impaired inhibitory performance during the Go/No-Go task and reduced activation in the middle temporal gyrus, superior/middle/inferior frontal gyrus and the anterior cingulate cortex. Third, the relationship between parahippocampal activation during response inhibition and inhibitory performance was different under placebo and LSD exposure. While parahippocampal activation correlates positively with the inhibitory performance after placebo treatment, no such relationship is evident after LSD administration. Finally, activation in the left superior frontal gyrus under LSD exposure is negatively related to subjective LSD-induced cognitive impairments and visual imageries.

Acute LSD administration significantly increased subjective feelings of impaired cognitive control and visual imageries, in line with other recent LSD studies (Schmid *et al.* 2015; Liechti *et al.* 2016; Carhart-Harris *et al.* 2016*a*; Preller *et al.* 2017). It has recently been shown that both of them can be blocked by the 5-HT_{2A}R antagonist ketanserin, indicating that these subjective LSD effects are mediated via 5-HT_{2A}R activation (Preller *et al.* 2017). Consistent with our first hypothesis, these self-ratings were positively related to each other, supporting the view that 5-HT_{2A}R activation by LSD might cause a cognitive disability to integrate new perception that triggers the formation of aberrant feelings and visual perception (Vollenweider & Geyer, 2001; Geyer & Vollenweider, 2008). The subjective effects of impaired cognitive control (e.g. I felt like a marionette, I felt isolated from everything and everyone, I was not able to complete a thought, my thought repeatedly became disconnected, I felt as though I were paralyzed) are phenomenologically similar to experiences of reality distortions. We have previously showed that acute LSD administration indeed increased the 'distance to reality' (Schmid *et al.* 2015). The here found relationship between impaired control and cognition and elementary imagery further suggest that impaired reality monitoring after LSD intake disrupts the ability to update internal representations and might thereby promote to the formation of visual imageries (e.g. I saw regular patterns in complete darkness or with closed eyes).



Fig. 3. (*a*) Significant difference in brain activation during response inhibition between the placebo and LSD treatment. Results are illustrated using a cluster-forming threshold $p < 0.001$ uncorrected, with an extent threshold of 20 voxels. (*b*) Significant different relationship between activation in the right parahippocampus (cluster size = 162, FWE corrected p value = 0.03, Z value = 4.95) and the probability of inhibition after placebo and LSD administration. (*c*) The magnitude of parahippocampal activation was positively correlated with the probability of inhibition in the placebo ($r = 0.660$, $p = 0.003$) but not LSD condition ($r = 0.40$, $p = 0.10$).

We also found that LSD impaired motor response inhibition during the Go/No-Go task as indexed by decreased probability of inhibition, an effect that was inversely related to the degree of subjective cognitive impairments after LSD administration. This finding might reflect an association between cognitive (inhibiting irrelevant mental processes) and behavioural (motor) inhibition (Bari & Robbins, 2013). In other words, LSD-induced feelings such as 'I had difficulty in distinguishing important from unimportant things' might have contributed to impairments in the inhibition of external stimuli (No-Go trials).

Furthermore, LSD reduced activation in key regions mediating response inhibition including the middle temporal gyrus, superior/middle/inferior frontal gyrus and the anterior cingulate cortex (Simmonds *et al.* 2008; Swick *et al.* 2011). Reduced activation in the right inferior frontal gyrus (Ford *et al.* 2004; Kaladjian *et al.* 2007), superior frontal gyrus (Ford *et al.* 2004), middle frontal gyrus (Ford *et al.* 2004; Arce *et al.* 2006), anterior cingulate cortex (Rubia *et al.* 2001; Ford *et al.* 2004; Arce *et al.* 2006), middle temporal gyrus (Ford *et al.* 2004) during response inhibition is also evident in schizophrenia patients. Furthermore,

Table 1. *Significant differences in brain activation during response inhibition between LSD and placebo administration in 18 healthy controls*

Comparison	Region	*p* value[a]	Cluster size	MNI co-ordinates (*X*/*Y*/*Z*)	R/L	*Z* value
PLA > LSD	Middle temporal gyrus	<0.0001	290[b]	56/−56/20	R	5.0494
				48/−66/26	R	4.2741
	Angular gyrus			50/−60/36	R	4.0033
	Postcentral gyrus	<0.0001	318[b]	−54/−12/44	L	4.9192
				−44/−16/46	L	4.8724
				−50/−8/52	L	4.4727
	Orbitofrontal cortex	0.6948	33	34/54/−8	R	4.6362
	Middle frontal gyrus	0.0667	88	24/52/32	R	4.5401
	Superior frontal gyrus			14/56/32	R	3.8251
	Middle frontal gyrus			32/46/36	R	3.5265
	Anterior cingulate cortex	0.0071	143[b]	8/38/28	R	4.4924
				6/30/30	R	3.8684
	Superior frontal gyrus			−2/42/28	L	3.7094
	Middle frontal gyrus (extending into the inferior frontal gyrus)	0.0198	117[b]	44/30/38	R	4.4192
				38/22/32	R	3.5836
	Middle frontal gyrus			36/30/46	R	3.3974
	Cerebellum	0.0352	103[b]	−26/−68/−36	L	4.3717
	Inferior frontal gyrus	0.9419	20	53/32/22	R	4.2450
	Middle frontal gyrus (extending into the inferior frontal gyrus)	0.2413	59	46/46/16	R	4.1100
				46/48/6	R	3.5461
	Middle frontal gyrus			38/58/12	R	3.2931
	Middle occipital lobule	0.6053	37	−42/−82/−4	L	4.0903
	Anterior cingulate cortex	0.0538	93	8/48/16	R	4.0604
				−2/50/14	L	3.9075
	Precuneus	0.6053	37	8/−56/58	R	3.9922
				10/−62/64	R	3.6832
	Middle temporal gyrus	0.6497	35	−66/−32/−6	L	3.9600
				−64/−24/0	L	3.4052
	Postcentral gyrus	0.6722	34	−28/−34/54	L	3.9504
	Rolandic operculum	0.6274	36	−40/−20/20	L	3.8458
				−46/−14/18	L	3.2402
				−46/−26/20	L	3.1788
	Superior temporal gyrus	0.8453	26	58/−12/−8	R	3.6555
	Fusiform gyrus	0.6722	34	34/−50/−18	R	3.5905
	Inferior frontal gyrus	0.9419	20	44/22/−18	R	3.5207
	Inferior temporal gyrus	0.9419	20	50/−66/−4	R	3.4904
				50/−60/−12	R	3.4002

Results are reported using a cluster-forming threshold $p < 0.001$ uncorrected, with an extent threshold of 20 voxels.
[a] Cluster-level FWE-corrected.
[b] Survives FWE correction for multiple comparisons at the cluster level.

deficits in sensorimotor gating have been found to be negatively related to grey matter volumes in the right dorsolateral prefrontal cortex in schizophrenia patients (Kumari *et al.* 2008). Interestingly with the respect to the relationship between cognitive control and visual hallucinations, a longitudinal study in patients with Parkinson's disease found that the visual hallucinators had greater grey matter loss in bilateral superior and inferior frontal gyrus, anterior cingulate gyrus and limbic areas including hippocampus. Patients with Parkinson's disease without visual hallucinations at baseline did not exhibit the same pattern of atrophy at follow-up and none had developed dementia (Ibarretxe-Bilbao *et al.* 2010).

More recently, increased connectivity has been shown between the anterior cingulate cortex and right dorsolateral prefrontal cortex during inhibition processes (Cieslik *et al.* 2013). Previous theories of cognitive control propose that when erroneous or conflicting behaviour is detected by the anterior cingulate



Fig. 4. Significant negative relationship between LSD-induced brain activation during response inhibition and (*a*) subjectively experienced cognitive impairments and (*b*) elementary imagery after LSD intake. Scatterplots showing the negative relationship between activation in the left superior frontal gyrus under LSD exposure and (*c*) subjectively experienced cognitive impairments ($r = -0.835$) and (*d*) elementary imagery ($r = -0.875$) after LSD administration.

cortex, it signals to the lateral prefrontal cortex and other regions responsible for maintaining goal-directed behaviour that greater levels of control are necessary to successfully perform a task (Botvinick *et al.* 2001; Brown & Braver, 2005; Johnston *et al.* 2007). Therefore, we can speculate that the LSD-induced reduction in anterior cingulate cortex activation reflects impaired error processing what in turn led to a decreased top–down signal to the prefrontal cortex regions to adapt goal-directed behaviour (missing learning from failed inhibitions).

We also found that right parahippocampal activation correlated positively with the inhibitory performance after placebo treatment, whereas no such relationship was evident after LSD administration. Similar to the function of the anterior cingulate cortex (Rubia *et al.* 2003), activation in the parahippocampus during response has previously been reported in response to errors with the goal to engage additional top–down resources to improve behaviour (Braet *et al.* 2011). Our finding might thus indicate that while people under placebo were able to learn from previous errors during the task and improve response inhibition via parahippocampal activation, acute LSD administration seemed to prevent a continuous improvement of task performance due to an impaired learning signal from the parahippocampus. The hippocampus and the anterior cingulate cortex work in concert during error processing; activation in the hippocampus correlated with error-feedback-related activation in the anterior cingulate cortex (Hester *et al.* 2008). Like the anterior cingulate cortex, the hippocampus is also functionally related to the lateral prefrontal cortex during inhibitory processing (Chudasama *et al.* 2012), and disruption of hippocampal–prefrontal interactions have been observed in psychiatric diseases, most notably in schizophrenia (Godsil *et al.* 2013; Sigurdsson & Duvarci, 2015). These findings together suggest that LSD impaired the error-related activation in the anterior cingulate cortex and parahippocampus and thereby impeded a subsequent recruitment of dorsolateral prefrontal regions (superior/middle/inferior frontal gyrus) to adjust further task performance.

Finally, there was a negative relationship between left superior frontal gyrus activation during response inhibition and subjective feelings of impaired cognitive control and visual hallucinations after LSD administration. Previous meta-analytical evidence revealed the involvement of the left superior frontal gyrus during response inhibition (Swick *et al.* 2011) and it has been shown that patients with left superior frontal gyrus lesions were globally impaired in cognitive control processes (du Boisgueheneuc *et al.* 2006). Decreased cortical thickness in the left superior frontal gyrus was related to decreased cognitive control in patients with schizophrenia (Tully *et al.* 2014). Moreover, the superior frontal gyrus was shown to be involved in the inhibition of internally represented information (Corbetta *et al.* 2002). Our results suggest that the subjective LSD-induced impairments in cognitive control (e.g. 'I had difficulty in distinguishing important from unimportant things', 'I was not able to complete a thought, my thought repeatedly became disconnected') might have contributed to an enhancement of internally generated representation and thereby impaired response inhibition via reduced activation in the superior frontal gyrus. This rekindling of internal representations (together with a neglect of external stimuli) possibly led to LSD-induced visual imageries. Supportive for this interpretation, previous studies showed that Parkinson patients with visual hallucinations had reduced grey matter volume in the left superior frontal gyrus compared to healthy controls (Gama *et al.* 2014) and less activation in the left superior frontal gyrus than non-hallucinating patients during the processing of complex visual-perceptual stimuli (Ramírez-Ruiz *et al.* 2008).

Taken together, our results show that LSD reduced activation in regions responsible for error detection such as the anterior cingulate cortex and parahippocampus during response inhibition, which might have led to an insufficient recruitment of dorsolateral prefrontal regions (i.e. superior/middle/inferior frontal gyrus) and in turn to an impaired learning from these errors to update goal-directed behaviour. This cascade and in particular reduced activation in the superior frontal gyrus after LSD administration finally might have shifted the focus away from external stimuli towards internally generated representation and possibly the formation of visual hallucinations. Of course, other brain areas are certainly also involved in the hallucinatory effects of LSD, in particular the visual cortex. It has been shown that LSD increased cerebral blood flow in the visual cortex and the functional connectivity to other brain regions, and both effects were correlated with complex imagery after LSD intake (Carhart-Harris *et al.* 2016*b*).

There are some limitations to be considered in the present study. Although we used a well-established paradigm from previous fMRI studies (Rubia *et al.* 2006; Schmitz *et al.* 2006; Borgwardt *et al.* 2008; Lawrence *et al.* 2009; Schmidt *et al.* 2013; Bhattacharyya *et al.* 2014; Daly *et al.* 2014; Bhattacharyya *et al.* 2015; Schmidt *et al.* 2017), we were not able to disentangle neural activation in response to successful *v.* failed inhibitions in the present study due to the modest number of No-Go trials. This also relativizes our interpretations that LSD effects on the anterior cingulate cortex and parahippocampus are probably related to impaired error processing. Due to the fast event-related design, the short event durations and the modest number of No-Go trials, the paradigm is further not well suited to address inhibition-induced connectivity within the neural response network. The here found relationship between cognitive impairments and visual imageries after LSD intake are correlative and should thus be considered with caution. Further studies are warranted to understand the causality of this relationship. To further disentangle the relationship between cognitive impairments and visual hallucinations after 5-HT_{2A}R stimulation, future studies might also want to conduct multiple tests to assess prefrontal-medicated cognitive control and reality monitoring processes. Having in mind that LSD did not only reduce the probability of inhibition during the task, but also decreased responses to Go trials and prolonged reaction times, a broad cognitive test battery should also help to explore if LSD specifically impairs response inhibition or rather cognitive processes in general. A further limitation of all studies using LSD is that blinding is difficult to maintain due to the subjective drug effects of the substance. We can therefore not exclude that expectations influenced the subjective drug effects of LSD, while this seems less likely for the neuronal activity patterns.

In summary, the present study showed that 5-HT_{2A} R activation by LSD led to deficits in inhibitory processing mediated via reduced parahippocampal–prefrontal activation in healthy volunteers. Our findings further provide a neuropsychopharmacological mechanism how impaired inhibitory processing might contribute to the formation of LSD-induced visual hallucinations. This study helps to better understand the neuropsychopharmacological mechanisms of visual hallucinations in LSD-induced states and neuropsychiatric disorders.

Supplementary Material

The supplementary material for this article can be found at https://doi.org/10.1017/S0033291717002914.

Acknowledgements

This work was supported by the Swiss National Science Foundation (grant no. 320030_170249 to MEL and SB).

Declaration of Interest

None.

References

Arce E, Leland DS, Miller DA, Simmons AN, Winternheimer KC, Paulus MP (2006). Individuals with schizophrenia present hypo- and hyperactivation during implicit cueing in an inhibitory task. *NeuroImage* **32**, 704–713.

Bari A, Robbins TW (2013). Inhibition and impulsivity: behavioral and neural basis of response control. *Progress in Neurobiology* **108**, 44–79.

Barnes J, Boubert L (2008). Executive functions are impaired in patients with Parkinson's disease with visual hallucinations. *Journal of Neurology, Neurosurgery and Psychiatry* **79**, 190–192.

Bhattacharyya S, Atakan Z, Martin-Santos R, Crippa JA, Kambeitz J, Malhi S, Giampietro V, Williams S, Brammer M, Rubia K, Collier DA, McGuire PK (2015). Impairment of inhibitory control processing related to acute psychotomimetic effects of cannabis. *European Neuropsychopharmacology* **25**, 26–37.

Bhattacharyya S, Iyegbe C, Atakan Z, Martin-Santos R, Crippa JA, Xu X, Williams S, Brammer M, Rubia K, Prata D, Collier DA, McGuire PK (2014). Protein kinase B (AKT1) genotype mediates sensitivity to cannabis-induced impairments in psychomotor control. *Psychological Medicine* **44**, 3315–3328.

Borgwardt SJ, Allen P, Bhattacharyya S, Fusar-Poli P, Crippa JA, Seal ML, Fraccaro V, Atakan Z, Martin-Santos R, O'Carroll C, Rubia K, McGuire PK (2008). Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. *Biological Psychiatry* **64**, 966–973.

Botvinick MM, Braver TS, Barch DM, Carter CS, Cohen JD (2001). Conflict monitoring and cognitive control. *Psychological Review* **108**, 624–652.

Braet W, Johnson KA, Tobin CT, Acheson R, McDonnell C, Hawi Z, Barry E, Mulligan A, Gill M, Bellgrove MA, Robertson IH, Garavan H (2011). fMRI activation during response inhibition and error processing: the role of the DAT1 gene in typically developing adolescents and those diagnosed with ADHD. *Neuropsychologia* **49**, 1641–1650.

Brown JW, Braver TS (2005). Learned predictions of error likelihood in the anterior cingulate cortex. *Science* **307**, 1118–1121.

Carhart-Harris RL, Kaelen M, Bolstridge M, Williams TM, Williams LT, Underwood R, Feilding A, Nutt DJ (2016a). The paradoxical psychological effects of lysergic acid diethylamide (LSD). *Psychological Medicine* **46**, 1379–1390.

Carhart-Harris RL, Leech R, Erritzoe D, Williams TM, Stone JM, Evans J, Sharp DJ, Feilding A, Wise RG, Nutt DJ (2013). Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis. *Schizophrenia Bulletin* **39**, 1343–1351.

Carhart-Harris RL, Muthukumaraswamy S, Roseman L, Kaelen M, Droog W, Murphy K, Tagliazucchi E, Schenberg EE, Nest T, Orban C, Leech R, Williams LT, Williams TM, Bolstridge M, Sessa B, McGonigle J, Sereno MI, Nichols D, Hellyer PJ, Hobden P, Evans J, Singh KD, Wise RG, Curran HV, Feilding A, Nutt DJ (2016b). Neural correlates of the LSD experience revealed by multimodal neuroimaging. *Proceedings of the National Academy of Sciences of the USA* **113**, 4853–4858.

Chudasama Y, Doobay VM, Liu Y (2012). Hippocampal-prefrontal cortical circuit mediates inhibitory response control in the rat. *Journal of Neuroscience* **32**, 10915–10924.

Cieslik EC, Zilles K, Caspers S, Roski C, Kellermann TS, Jakobs O, Langner R, Laird AR, Fox PT, Eickhoff SB (2013). Is there 'one' DLPFC in cognitive action control? Evidence for heterogeneity from co-activation-based parcellation. *Cerebral Cortex* **23**, 2677–2689.

Corbetta M, Kincade JM, Shulman GL (2002). Neural systems for visual orienting and their relationships to spatial working memory. *Journal of Cognitive Neuroscience* **14**, 508–523.

Daly E, Ecker C, Hallahan B, Deeley Q, Craig M, Murphy C, Johnston P, Spain D, Gillan N, Gudbrandsen M, Brammer M, Giampietro V, Lamar M, Page L, Toal F, Schmitz N, Cleare A, Robertson D, Rubia K, Murphy DG (2014). Response inhibition and serotonin in autism: a functional MRI study using acute tryptophan depletion. *Brain* **137**, 2600–2610.

De Gregorio D, Comai S, Posa L, Gobbi G (2016). d-Lysergic acid diethylamide (LSD) as a model of psychosis: mechanism of action and pharmacology. *International Journal of Molecular Sciences* **17**, doi: 10.3390/ijms17111953.

Dolder PC, Liechti ME, Rentsch KM (2015a). Development and validation of a rapid turboflow LC-MS/MS method for the quantification of LSD and 2-oxo-3-hydroxy LSD in serum and urine samples of emergency toxicological cases. *Analytical and Bioanalytical Chemistry* **407**, 1577–1584.

Dolder PC, Schmid Y, Haschke M, Rentsch KM, Liechti ME (2015b). Pharmacokinetics and concentration-effect relationship of oral LSD in humans. *International Journal of Neuropsychopharmacology*, https://doi.org/10.1093/ijnp/pyv072.

Dolder PC, Schmid Y, Müller F, Borgwardt S, Liechti ME (2016). LSD acutely impairs fear recognition and enhances emotional empathy and sociality. *Neuropsychopharmacology* **41**, 2638–2646.

Dolder PC, Schmid Y, Steuer AE, Kraemer T, Rentsch KM, Hammann F, Liechti ME (2017). Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide in healthy subjects. *Clinical Pharmacokinetics*, https://doi.org.10.1007/s40262-017-0513-9.

du Boisgueheneuc F, Levy R, Volle E, Seassau M, Duffau H, Kinkingnehun S, Samson Y, Zhang S, Dubois B (2006).

Functions of the left superior frontal gyrus in humans: a lesion study. *Brain* **129**, 3315–3328.

Ford JM, Gray M, Whitfield SL, Turken AU, Glover G, Faustman WO, Mathalon DH (2004). Acquiring and inhibiting prepotent responses in schizophrenia: event-related brain potentials and functional magnetic resonance imaging. *Archives of General Psychiatry* **61**, 119–129.

Gama RL, Bruin VM, Távora DG, Duran FL, Bittencourt L, Tufik S (2014). Structural brain abnormalities in patients with Parkinson's disease with visual hallucinations: a comparative voxel-based analysis. *Brain and Cognition* **87**, 97–103.

Geyer MA, Vollenweider FX (2008). Serotonin research: contributions to understanding psychoses. *Trends in Pharmacological Sciences* **29**, 445–453.

Godsil BP, Kiss JP, Spedding M, Jay TM (2013). The hippocampal-prefrontal pathway: the weak link in psychiatric disorders? *European Neuropsychopharmacolog* **23**, 1165–1181.

González-Maeso J, Sealfon S (2009). Psychedelics and schizophrenia. *Trends in Pharmacological Sciences* **32**, 225–232.

Grossi D, Carotenuto A, Trojano L, Manzo V, Fasanaro AM (2011). Do frontal dysfunctions play a role in visual hallucinations in Alzheimer's disease as in Parkinson's disease? A comparative study. *Psychology & Neuroscience* **4**, 385–389.

Halberstadt AL, Geyer MA (2013). Serotonergic hallucinogens as translational models relevant to schizophrenia. *International Journal of Neuropsychopharmacology* **16**, 2165–2180.

Hester R, Barre N, Murphy K, Silk TJ, Mattingley JB (2008). Human medial frontal cortex activity predicts learning from errors. *Cerebral Cortex* **18**, 1933–1940.

Ibarretxe-Bilbao N, Ramirez-Ruiz B, Junque C, Marti MJ, Valldeoriola F, Bargallo N, Juanes S, Tolosa E (2010). Differential progression of brain atrophy in Parkinson's disease with and without visual hallucinations. *Journal of Neurology, Neurosurgery and Psychiatry* **81**, 650–657.

Johnston K, Levin HM, Koval MJ, Everling S (2007). Top-down control-signal dynamics in anterior cingulate and prefrontal cortex neurons following task switching. *Neuron* **53**, 453–462.

Kaladjian A, Jeanningros R, Azorin JM, Grimault S, Anton JL, Mazzola-Pomietto P (2007). Blunted activation in right ventrolateral prefrontal cortex during motor response inhibition in schizophrenia. *Schizophrenia Research* **97**, 184–193.

Kometer M, Schmidt A, Jäncke L, Vollenweider FX (2013). Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations. *Journal of Neuroscience* **33**, 10544–10551.

Kometer M, Vollenweider FX (2016). Serotonergic hallucinogen-induced visual perceptual alterations. *Current Topics in Behavioral Neurosciences*, https://doi.org/10.1007/7854_2016_461.

Krus DM, Wapner S, Freeman H, Casey TM (1963). Differential behavioral responsivity to LSD-25, study in normal and schizophrenic adults. *Archives of General Psychiatry* **8**, 557–563.

Kumari V, Fannon D, Geyer MA, Premkumar P, Antonova E, Simmons A, Kuipers E (2008). Cortical grey matter volume and sensorimotor gating in schizophrenia. *Cortex* **44**, 1206–1214.

Lawrence EJ, Rubia K, Murray RM, McGuire PK, Walshe M, Allin M, Giampietro V, Rifkin L, Williams SC, Nosarti C (2009). The neural basis of response inhibition and attention allocation as mediated by gestational age. *Human Brain Mapping* **30**, 1038–1050.

Liechti ME, Dolder PC, Schmid Y (2016). Alterations of consciousness and mystical-type experiences after acute LSD in humans. *Psychopharmacology* **234**, 1499–1510.

Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, Friedman JH (2010). Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of Parkinson's disease psychosis. *Neuropsychopharmacology* **35**, 881–892.

Preller KH, Herdener M, Pokorny T, Planzer A, Kraehenmann R, Stämpfli P, Liechti ME, Seifritz E, Vollenweider FX (2017). The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. *Current Biology* **27**, 451–457.

Quednow BB, Kometer M, Geyer MA, Vollenweider FX (2011). Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. *Neuropsychopharmacology* **37**, 630–640.

Ramírez-Ruiz B, Martí MJ, Tolosa E, Falcón C, Bargalló N, Valldeoriola F, Junqué C (2008). Brain response to complex visual stimuli in Parkinson's patients with hallucinations: a functional magnetic resonance imaging study. *Movement Disorders* **23**, 2335–2343.

Roth BL, Hanizavareh SM, Blum AE (2004). Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. *Psychopharmacology* **174**, 17–24.

Roth JK, Johnson MK, Raye CL, Constable RT (2009). Similar and dissociable mechanisms for attention to internal versus external information. *NeuroImage* **48**, 601–608.

Rubia K, Russell T, Bullmore ET, Soni W, Brammer MJ, Simmons A, Taylor E, Andrew C, Giampietro V, Sharma T (2001). An fMRI study of reduced left prefrontal activation in schizophrenia during normal inhibitory function. *Schizophrenia Research* **52**, 47–55.

Rubia K, Smith AB, Brammer MJ, Taylor E (2003). Right inferior prefrontal cortex mediates response inhibition while mesial prefrontal cortex is responsible for error detection. *NeuroImage* **20**, 351–358.

Rubia K, Smith AB, Woolley J, Nosarti C, Heyman I, Taylor E, Brammer M (2006). Progressive increase of frontostriatal brain activation from childhood to adulthood during event-related tasks of cognitive control. *Human Brain Mapping* **27**, 973–993.

Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, Brenneisen R, Müller F, Borgwardt S, Liechti ME (2015). Acute effects of lysergic acid

diethylamide in healthy subjects. *Biological Psychiatry* **78**, 544–553.

Schmidt A, Müller F, Dolder PC, Schmid Y, Zanchi D, Liechti ME, Borgwardt S (2017). Comparative effects of methylphenidate, modafinil and MDMA on response inhibition neural networks in healthy subjects. *International Journal of Neuropsychopharmacology* **20**, 712–720.

Schmidt A, Walter M, Gerber H, Schmid O, Smieskova R, Bendfeldt K, Wiesbeck GA, Riecher-Rössler A, Lang UE, Rubia K, McGuire P, Borgwardt S (2013). Inferior frontal cortex modulation with an acute dose of heroin during cognitive control. *Neuropsychopharmacology* **38**, 2231–2239.

Schmitz N, Rubia K, Daly E, Smith A, Williams S, Murphy DG (2006). Neural correlates of executive function in autistic spectrum disorders. *Biological Psychiatry* **59**, 7–16.

Sigurdsson T, Duvarci S (2015). Hippocampal-prefrontal interactions in cognition, behavior and psychiatric disease. *Frontiers in Systems Neuroscience* **9**, 190.

Simmonds DJ, Pekar JJ, Mostofsky SH (2008). Meta-analysis of Go/No-go tasks demonstrating that fMRI activation associated with response inhibition is task-dependent. *Neuropsychologia* **46**, 224–232.

Steeds H, Carhart-Harris RL, Stone JM (2015). Drug models of schizophrenia. *Therapeutic Advances in Psychopharmacology* **5**, 43–58.

Štrac DŠ, Pivac N, Mück-Šeler D (2016). The serotonergic system and cognitive function. *Translational Neuroscience* **7**, 35–49.

Studerus E, Gamma A, Vollenweider FX (2010). Psychometric evaluation of the altered states of consciousness rating scale (OAV). *PLoS ONE* **5**, e12412.

Swick D, Ashley V, Turken U (2011). Are the neural correlates of stopping and not going identical? Quantitative meta-analysis of two response inhibition tasks. *NeuroImage* **56**, 1655–1665.

Tully LM, Lincoln SH, Liyanage-Don N, Hooker CI (2014). Impaired cognitive control mediates the relationship between cortical thickness of the superior frontal gyrus and role functioning in schizophrenia. *Schizophrenia Research* **152**, 358–364.

Vollenweider F, Vollenweider-Scherpenhuyzen M, Bäbler A, Vogel H, Hell D (1998). Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. *Neuroreport* **9**, 3897–3902.

Vollenweider FX, Geyer MA (2001). A systems model of altered consciousness: integrating natural and drug-induced psychoses. *Brain Research Bulletin* **56**, 495–507.

Wapner S, Krus DM (1960). Effects of lysergic acid diethylamide, and differences between normals and schizophrenics on the Stroop Color-Word Test. *Journal of Neuropsychiatry* **2**, 76–81.

Woo CW, Krishnan A, Wager TD (2014). Cluster-extent based thresholding in fMRI analyses: pitfalls and recommendations. *NeuroImage* **91**, 412–419.

Zhang G, Stackman RW (2015). The role of serotonin 5-HT2A receptors in memory and cognition. *Frontiers in Pharmacology* **6**, 225.